Literature DB >> 16164692

MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.

E Lugli1, M Pinti, M Nasi, L Troiano, N Prada, C Mussini, V Borghi, R Esposito, A Cossarizza.   

Abstract

Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16164692     DOI: 10.1111/j.1744-313X.2005.00523.x

Source DB:  PubMed          Journal:  Int J Immunogenet        ISSN: 1744-3121            Impact factor:   1.466


  2 in total

1.  Marked relationship between matrix metalloproteinase 7 and brain atrophy in HIV infection.

Authors:  Ann B Ragin; Ying Wu; Renee Ochs; Hongyan Du; Leon G Epstein; Katherine Conant; Justin C McArthur
Journal:  J Neurovirol       Date:  2011-02-08       Impact factor: 2.643

2.  Serum matrix metalloproteinase levels correlate with brain injury in human immunodeficiency virus infection.

Authors:  Ann B Ragin; Ying Wu; Renee Ochs; Rachel Scheidegger; Bruce A Cohen; Justin C McArthur; Leon G Epstein; Katherine Conant
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 2.643

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.